A Phase II Study of Intravenous DX-8951f [exatecan] Administered Daily for Five Days Every Three Weeks to Patients With Advanced or Recurrent Squamous Cell Cancer of the Cervix
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Exatecan (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- 25 Oct 2007 Status changed from suspended to completed.
- 11 Sep 2005 New trial record.